Phase II Trial Evaluating Irinotecan and Capecitabine Relapsed/Refractory Upper GI Tumours
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to assess the efficacy and toxicity of a 3 weekly regimen
containing irinotecan combined with capecitabine in the setting of relapsed or refractory
upper gastrointestinal tumours. Patients with locally advanced or metastatic adenocarcinoma
or squamous cell carcinoma originating from the oesophagus, oesophagogastric junction or
stomach who have previously received chemotherapy and have either failed to respond or who
have relapsed within 3 months after an initial response will be eligible for treatment in
this study.
The response rate, failure-free survival and overall survival of treated patients will be
evaluated. Toxicity and quality of life will also be monitored closely.